<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04246151</url>
  </required_header>
  <id_info>
    <org_study_id>DECENCY-RCT</org_study_id>
    <nct_id>NCT04246151</nct_id>
  </id_info>
  <brief_title>Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients</brief_title>
  <acronym>Decency-RCT</acronym>
  <official_title>Oral Vancomycin Versus Probiotics Versus Placebo for Prevention of Clostridium Difficile Infection in Colonized Patients (Decency-RCT): A Randomized Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this pilot study is to assess the feasibility of randomizing hospitalized
      patients that are colonized with C. difficile and started on systemic antibiotics to either a
      probiotic, oral vancomycin, or placebo in a parallel-group 1:1:1 design. The ultimate goal is
      to conduct an appropriately-powered RCT to determine the optimal method for reducing C
      difficile infection in colonized patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, patients will be screened for C. difficile colonization
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patients will be randomized to receive either a probiotic, oral vancomycin, or placebo in a parallel-group 1:1:1 design.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Blinding will be done in a double-blind fashion. The patients, their caregiver, and the investigator will be blinded to the study treatment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of screening for and randomizing C difficile colonized patients to one of the treatment arms within 72 hours of starting on a systematic antibiotic.</measure>
    <time_frame>1 year</time_frame>
    <description>Feasibility will be assessed using the following parameters:
Proportion of eligible participants screened that are randomized within 72 hours of antibiotic exposure (goal ≥ 90%)
Proportion of participants receiving all doses of study medication (goal ≥ 90%)
Proportion of participants with complete follow up at 14 days (goal ≥ 95%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of C difficile associated diarrhea within 14 days of randomization</measure>
    <time_frame>1 year</time_frame>
    <description>We will assess the development of C difficile associated diarrhea within 14 days of randomization to one of the treatment arms as defined by the Provincial Infectious Diseases Advisory Committee (PIDAC)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Clostridium Difficile Colonization</condition>
  <condition>Clostridium Difficile Diarrhea</condition>
  <arm_group>
    <arm_group_label>Vancomycin &amp; probiotic placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vancomycin 125 mg orally every 12 hours plus probiotic placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic &amp; vancomycin placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Culturelle probiotic 20 billion active units orally every 12 hours plus vancomycin placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probiotic placebo &amp; vancomycin placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vancomycin placebo orally every 12 hours and Culturelle placebo orally every 12 hours for the duration of systematic antibiotic for a maximum of 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin capsules</description>
    <arm_group_label>Vancomycin &amp; probiotic placebo</arm_group_label>
    <other_name>JAMP-vancomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Culturelle</intervention_name>
    <description>Culturelle capsules</description>
    <arm_group_label>Probiotic &amp; vancomycin placebo</arm_group_label>
    <other_name>Lactobacillus rhamnosus GG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin Placebo</intervention_name>
    <description>sugar pill manufactured to mimic the vancomycin 125 mg capsule</description>
    <arm_group_label>Probiotic &amp; vancomycin placebo</arm_group_label>
    <arm_group_label>Probiotic placebo &amp; vancomycin placebo</arm_group_label>
    <other_name>Placebo for Vancomycin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Probiotic Placebo</intervention_name>
    <description>sugar pill manufactured to mimic 10 billion unit probiotic capsules.</description>
    <arm_group_label>Probiotic placebo &amp; vancomycin placebo</arm_group_label>
    <arm_group_label>Vancomycin &amp; probiotic placebo</arm_group_label>
    <other_name>Placebo for probiotic</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients of 18 years of age or older identified as asymptomatic carriers of C.
             difficile (i.e. not meeting case definition of C. difficile infection, see below)

          -  Started on systemic (oral or intravenous) antibiotics for any (presumed) bacterial
             infection

          -  Patient must have vitals (heart rate, blood pressure, temperature), estimated
             creatinine clearance (using the Chronic Kidney Disease Epidemiology equation
             (CKD-Epi)) and a complete blood count available within 24 hours of enrolment

        Exclusion Criteria:

          -  On a course of systemic antibiotics that had been started more than 72 hours ago (as
             current evidence suggests that the earlier probiotics are started, the more
             efficacious they are)

          -  Patient with C. difficile, i.e. presence of diarrhea (three or more loose or watery
             stools within 24 hours), or fevers or hypotension from C. difficile infection

          -  Any patients with contra-indications to probiotics or vancomycin:

               -  Immunosuppressed (primary or acquired immunodeficiency, including AIDS (defined
                  as AIDS defining condition or cluster of differentiation 4 (CD4) nadir of
                  &lt;200/ul), hematologic malignancies, long-term systemic corticosteroid treatment,
                  active treatment with chemotherapeutic agents or biologicals, autoimmune
                  diseases, nephrotic syndrome)

               -  Structural heart disease (e.g. atrial septal defect, ventricular septal defect)

               -  Gastroesophageal or compromised gut integrity (e.g. short gut syndrome,
                  intestinal injury or dysfunction, inflammatory bowel diseases including current
                  or past history of Crohn's disease and ulcerative colitis)

               -  Patients on systemic aminoglycosides, ethacrynic acid, polymixin B, or colistin.

               -  Prior or current hearing loss

               -  Female patients with known pregnancy or who are planning to get pregnant, or who
                  are breastfeeding

               -  Patients with end-stage renal diseases defined as an estimated glomerular
                  filtration rate of &lt;15ml/min, or absence of a current estimated creatinine
                  clearance

               -  History of an allergic reaction to one of the study drugs, or sensitivity to milk

          -  Patients started on probiotics or oral vancomycin while in hospital
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dominik Mertz, MD</last_name>
    <phone>905-525-9140</phone>
    <phone_ext>43952</phone_ext>
    <email>mertz@hhsc.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jodi Gilchrist, MSc</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>33454</phone_ext>
    <email>jgilchri@stjoes.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Marek Smieja, MD/PhD</last_name>
      <phone>905-521-6021</phone>
      <email>smiejam@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jodi Gilchrist, MSc</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>33454</phone_ext>
      <email>jgilchri@stjoes.ca</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 1C3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Dominik Mertz, MD</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>43952</phone_ext>
      <email>Mertz@hhsc.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jodi Gilchrist, MSc</last_name>
      <phone>905-522-1155</phone>
      <phone_ext>33454</phone_ext>
      <email>jgilchri@stjoes.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Mark Loeb, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 20, 2020</study_first_submitted>
  <study_first_submitted_qc>January 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2020</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clostridium Infections</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data will be shared with researchers that are not directly involved in this study. Overall data will be shared in the context of peer reviewed journal publications or scientific presentations.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

